An internationally generalizable risk index for mortality after one year of antiretroviral therapy

AIDS

Volumn 27, Issue 4, 2013, Pages 563-572

  Tate, Janet P ^a   Justice, Amy C ^a   Hughes, Michael D ^b   Bonnet, Fabrice ^c   Reiss, Peter ^d   Mocroft, Amanda ^e   Nattermann, Jacob ^f   Lampe, Fiona C ^e   Bucher, Heiner C ^g   Sterling, Timothy R ^h   Crane, Heidi M ⁱ   Kitahata, Mari M ^j   May, Margaret ^k   Sterne, Jonathan A C ^k  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITÉ DE BORDEAUX   (France)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^f UNIVERSITY OF BONN   (Germany)

^g UNIVERSITY HOSPITAL BASEL   (Switzerland)

^h VANDERBILT UNIVERSITY   (United States)

ⁱ Center for AIDS Research   (United States)

^j UNIVERSITY OF WASHINGTON   (United States)

^k UNIVERSITY OF BRISTOL   (United Kingdom)

more..

Author keywords

anemia; cohort study; comorbidity; FIB 4; HIV; mortality; prognostic index

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; VIRUS RNA;

ADULT; AGE DISTRIBUTION; AGED; ANTIVIRAL THERAPY; ARTICLE; CAUSE OF DEATH; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DISCRIMINANT ANALYSIS; FEMALE; GENDER; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MORTALITY; PRIORITY JOURNAL; RESTRICTED INDEX; VETERANS AGING COHORT STUDY RISK INDEX;

ADULT; AGE FACTORS; AGED; ALANINE TRANSAMINASE; ANTI-HIV AGENTS; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; EUROPE; FEMALE; HEMOGLOBINS; HEPATITIS C; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; PLATELET COUNT; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RNA, VIRAL; UNITED STATES;

EID: 84873409832     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835b8c7f     Document Type: Article

References (40)

1. Mocroft A, Sterne JA, Egger M, May M, Grabar S, Furrer H, et al. Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal. Clin Infect Dis 2009; 48:1138-1151.
2. D'Arminio MA, Sabin CA, Phillips A, Sterne J, May M, Justice A, et al. The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. Arch Intern Med 2005; 165:416-423.
3. Deeks SG, Phillips AN. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ 2009; 338: a3172.
4. Justice AC. HIV and aging: time for a new paradigm. Curr HIV/ AIDS Rep 2010; 7:69-76.
5. Kuller LH, Tracy R, Belloso W, De WS, Drummond F, Lane HC, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5:e203.
6. Sandler NG, Wand H, Roque A, Law M, Nason MC, Nixon DE, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 2011; 203:780-790.
7. Justice AC, Freiberg MS, Tracy R, Kuller L, Tate JP, Goetz MB, et al. Does an index composed of clinical data reflect effects of inflammation, coagulation, and monocyte activation on mortality among those aging with HIV? Clin Infect Dis 2012; 54:984-994.
8. Neuhaus J, Jacobs DR Jr, Baker JV, Calmy A, Duprez D, La RA, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 2010; 201:1788-1795.
9. Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 2006; 113: 2335-2362.
10. Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Washington, DC: Department of Health and Human Services/Henry J. Kaiser Family Foundation; 2005. pp. 1-97.
11. Aberg JA, Kaplan JE, Libman H, Emmanuel P, Anderson JR, Stone VE, et al. Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2009; 49:651-681.
12. May M, Royston P, Egger M, Justice AC, Sterne JA, ART-CC. Development and validation of a prognostic model for survival time data: application to prognosis of HIV positive patients treated with antiretroviral therapy. Stat Med 2004; 23:2375- 2398.
13. Srasuebkul P, Lim PL, Lee MP, Kumarasamy N, Zhou J, Sirisanthana T, et al. Short-term clinical disease progression in HIV-infected patients receiving combination antiretroviral therapy: results from the TREAT Asia HIV observational database. Clin Infect Dis 2009; 48:940-950.
14. Lundgren JD, Mocroft A, Gatell JM, Ledergerber B, D'Arminio MA, Hermans P, et al. A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: results from the EuroSIDA study. J Infect Dis 2002; 185:178-187.
15. Harris RJ, Sterne JA, Abgrall S, Dabis F, Reiss P, Saag M, et al. Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies. Antivir Ther 2008; 13:959-967.
16. Justice AC, McGinnis KA, Skanderson M, Chang CC, Gibert CL, Goetz MB, et al. Towards a combined prognostic index for survival in HIV infection: the role of 'non-HIV' biomarkers. HIV Med 2010; 11:143-151.
17. Fultz SL, Skanderson M, Mole LA, Gandhi N, Bryant K, Crystal S, et al. Development and verification of a 'virtual' cohort using the National VA Health Information System. Med Care 2006; 44 (8 Suppl 2):S25-S30.
18. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119-129.
19. Boyle CA, Decoufle P. National sources of vital status information: extent of coverage and possible selectivity in reporting. Am J Epidemiol 1990; 131:160-168.
20. Fisher SG, Weber L, Goldberg J, Davis F. Mortality ascertainment in the veteran population: alternatives to the National Death Index. Am J Epidemiol 1995; 141:242-250.
21. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43:1317-1325.
22. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function: measured and estimated glomerular filtration rate. N Engl J Med 2006; 354:2473-2483.
23. Kowalska JD, Friis-Moller N, Kirk O, Bannister W, Mocroft A, Sabin C, et al. The Coding Causes of Death in HIV (CoDe) Project: initial results and evaluation of methodology. Epidemiology 2011; 22:516-523.
24. Antiretroviral Therapy Cohort Collaboration (ART-CC). Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 2010; 50:1387- 1396.
25. Newson R. Confidence intervals for rank statistics: Somers' D and extensions. Stata J 2006; 6:309-334.
26. Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 2007; 115:928- 935.
27. Yourman LC, Lee SJ, Schonberg MA, Widera EW, Smith AK. Prognostic indices for older adults: a systematic review. JAMA 2012; 307:182-192.
28. Donders AR, van der Heijden GJ, Stijnen T, Moons KG. Review: a gentle introduction to imputation of missing values. J Clin Epidemiol 2006; 59:1087-1091.
29. Justice AC, Covinsky KE, Berlin JA. Assessing the generalizability of prognostic information. Ann Intern Med 1999; 130:515-524.
30. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97:1837-1847.
31. Tate J, Freiberg M, Justice AC. Do risk factors for cardiovascular disease improve VACS Index prediction of all cause mortality? 16th International Workshop on HIV Observational Databases, Athens; 2012.
32. Sullivan LM, Massaro JM, D'Agostino RB Sr. Presentation of multivariate data for clinical use: The Framingham Study risk score functions. Stat Med 2004; 23:1631-1660.
33. Deeks SG. Immune dysfunction, inflammation, and accelerated aging in patients on antiretroviral therapy. Top HIV Med 2009; 17:118-123.
34. Leone S, Gregis G, Quinzan G, Velenti D, Cologni G, Soavi L, et al. Causes of death and risk factors among HIV-infected persons in the HAART era: analysis of a large urban cohort. Infection 2011; 39:13-20.
35. Effros RB, Fletcher CV, Gebo K, Halter JB, Hazzard WR, Horne FM, et al. Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions. Clin Infect Dis 2008; 47:542-553.
36. Phillips AN, Neaton J, Lundgren JD. The role of HIV in serious diseases other than AIDS. AIDS 2008; 22:2409-2418.
37. Silverberg MJ, Neuhaus J, Bower M, Gey D, Hatzakis A, Henry K, et al. Risk of cancers during interrupted antiretroviral therapy in the SMART study. AIDS 2007; 21: 1957-1963.
38. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, et al. CD4R count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283- 2296.
39. Casey BM, McIntire DD, Leveno KJ. The continuing value of the Apgar score for the assessment of newborn infants. N Engl J Med 2001; 344:467-471.
40. Beutler E, Waalen J. The definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration? Blood 2006; 107:1747-1750.